Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Feb 1;11(2):168.
doi: 10.1038/nrd3560-c1.

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

Brad Spellberg, Priya Sharma, John H Rex
Comment

The critical impact of time discounting on economic incentives to overcome the antibiotic market failure

Brad Spellberg et al. Nat Rev Drug Discov. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

In the past 12 months, B.S. has received: research grants and contracts from Cubist, Pfizer and Eisai; consulting fees paid into an institutional account from GlaxoSmithKline, Pfizer, Basilea, The Medicines Company, Achaogen, Trius, Eisai, Meiji, Polymedix and BioCritica; and speaker’s fees from Cubist, AstraZeneca and Achaogen. J.H.R. is an employee and shareholder of AstraZeneca. P.S. declares no competing financial interests.

Comment on

  • Antibacterial R&D incentives.
    Laxminarayan R, Powers JH. Laxminarayan R, et al. Nat Rev Drug Discov. 2011 Sep 30;10(10):727-8. doi: 10.1038/nrd3560. Nat Rev Drug Discov. 2011. PMID: 21959280 No abstract available.

References

    1. Powers JH, Laxminarayan R. Antibacterial R&D incentives. Nature Rev Drug Discov. 2011;10:727–728. - PubMed
    1. European Medicines Agency. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. EMA website [online] 2009 www.ema.europa.eu/pdfs/human/antimicrobial_resistance/53394009en.pdf.
    1. Spellberg B, et al. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52:S397–S428. - PMC - PubMed
    1. Mossialos E, et al. Policies and incentives for promoting innovation in antibiotic research. LSE website [online] 2009 http://www2.lse.ac.uk/LSEHealthAndSocialCare/LSEHealth/News/Antibiotics%....
    1. Infectious Diseases Society of America. Bad bugs, no drugs: as antibiotic discovery stagnates, a public health crisis brews. IDSA website [online] 2004 http://www.idsociety.org/uploadedFiles/IDSA/Policy_and_Advocacy/Current_....

Substances